Payment overview · 2025
General Payments
$1,219.05
42 reported records · 14 companies
Healthcare provider profile · identity verified
Jeffrey Brian Hoag, MD, MS
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · PHILADELPHIA, PA · NPI 1457356917
Verified facts
What the public records show
CMS Open Payments records show Jeffrey Brian Hoag, MD, MS received $1,219.05 in general payments during 2025 across 42 reported records.
Insmed, Inc. accounted for 22.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arikayce, Tezspire, Trelegy Ellipta, Zenpep.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TEZSPIRE as an associated drug or biological on 22824 records involving 7320 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Tezspire by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Symbicort by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TEZSPIRE as an associated drug or biological on 33983 records involving 10291 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Tezspire by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 195 claims for Trelegy Ellipta by this doctor in 2024.
Insmed, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Arikayce as an associated drug or biological on 32500 records involving 8305 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Arikayce by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Insmed, Inc. | Unresolved — no canonical attribution shown | $274.22 | 22.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $192.62 | 15.8% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $190.57 | 15.6% | 9 | 2025 |
| Galvanize Therapeutics, Inc | Unresolved — no canonical attribution shown | $141.44 | 11.6% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $106.13 | 8.7% | 5 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $65.55 | 5.4% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $47.85 | 3.9% | 2 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $45.87 | 3.8% | 1 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $35.96 | 3.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $35.07 | 2.9% | 2 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $26.84 | 2.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.30 | 1.9% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $17.01 | 1.4% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $16.62 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,219.05 | 42 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $274.22 | 2 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $178.64 | 11 | 2025 |
Source payment records
|
|||||
| ALIYA SYSTEM Normalized: aliya system |
Device | Galvanize Therapeutics, Inc | $141.44 | 1 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $119.19 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $113.38 | 5 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $106.13 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $67.53 | 2 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $66.81 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $47.85 | 2 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $45.87 | 1 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $35.96 | 1 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $33.20 | 1 | 2025 |
Source payment records
|
|||||
| Xembify Normalized: xembify |
Biological | Grifols USA, LLC | $32.35 | 1 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $26.84 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $23.30 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $17.01 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $16.62 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $13.98 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Arikayce arikayce |
2025 | Arikayce | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TEZSPIRE tezspire |
2025 | Tezspire | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 195 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 52 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | TEZSPIRE open payments reported associated product |
CMS Open Payments — General Payments 22824 supporting records · 7320 recipient NPIs · example record 1226871881 |
Tezspire · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
35 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | TEZSPIRE open payments reported associated product |
CMS Open Payments — General Payments 33983 supporting records · 10291 recipient NPIs · example record 1206131392 |
Tezspire · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
195 | 40 |
| Insmed, Inc. Exact reporting entity; no affiliate inference |
2025 | Arikayce open payments reported associated product |
CMS Open Payments — General Payments 32500 supporting records · 8305 recipient NPIs · example record 1186254431 |
Arikayce · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Albuterol Sulfate Hfa | Albuterol Sulfate | 406 | 103 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 195 | 40 |
| Trikafta | Elexacaftor/Tezacaftor/Ivacaft | 165 | 15 |
| Prednisone | Prednisone | 114 | 48 |
| Azithromycin | Azithromycin | 107 | 40 |
| Montelukast Sodium | Montelukast Sodium | 70 | 28 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 63 | 16 |
| Spiriva Respimat | Tiotropium Bromide | 63 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 59 | 15 |
| Zenpep | Lipase/Protease/Amylase | 52 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 50 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 49 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 47 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 41 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 35 | 12 |
| Ursodiol | Ursodiol | 33 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 32 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 30 | suppressed |
| Arikayce | Amikacin Liposomal/Neb.Accessr | 27 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Tezspire | Tezepelumab-Ekko | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | suppressed |
| Omeprazole | Omeprazole | 17 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Dupixent Pen | Dupilumab | 16 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | suppressed |
| Pertzye | Lipase/Protease/Amylase | 16 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 14 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Cayston | Aztreonam Lysine | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Epinephrine | Epinephrine | 12 | suppressed |
| Famotidine | Famotidine | 12 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 12 | suppressed |
| Xolair | Omalizumab | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,219.05 · 42 records | Insmed, Inc. | ACTHAR, AIRSUPRA, ALIYA SYSTEM, Arikayce, BREZTRI, DUPIXENT, FASENRA, NUCALA, Ohtuvayre, Prolastin-C Liquid, SMARTVEST, TEZSPIRE, TRELEGY ELLIPTA, Vest Therapy Und, Xembify, YUPELRI, ZENPEP, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arikayce play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Aimmune Therapeutics, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error